U.S. House · 117th Congress · H.R. 2891
Preserve Access to Affordable Generics and Biosimilars Act
To prohibit prescription drug companies from compensating other prescription drug companies to delay the entry of a generic drug, biosimilar biological product, or interchangeable biological product into the market.
Follow
Log in to follow this bill and get an email when there’s a new vote (premium).
- Sponsor
- Jerrold NadlerD-NY-10
- Introduced
- April 28, 2021, in the House
- Issue areas
- Policy area
- Health (from the Congressional Research Service)
- Full text and actions
- congress.gov
Votes on this bill (0)
Neither the House nor the Senate has held a roll-call vote on this bill.
Cosponsors (7)
4 Democrats, 3 Republicans. Each member is shown with the party they were counted with on the day they signed on. How we count these
Original cosponsors
- Ken BuckR-CO-4
- David N. CicillineD-RI-1
- Carolyn B. MaloneyD-NY-12
Signed on later
- Burgess OwensR-UT-4May 28, 2021
- Eleanor Holmes NortonD-DC-ALJuly 20, 2021
- Ted BuddR-NC-13September 24, 2021
- Sheila Jackson LeeD-TX-18September 28, 2021